Patrick Soon - Feb 10, 2025 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Signature
/s/ Patrick Soon-Shiong
Stock symbol
IBRX
Transactions as of
Feb 10, 2025
Transactions value $
$0
Form type
4
Date filed
2/12/2025, 08:17 PM
Previous filing
Dec 12, 2024
Next filing
Feb 25, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Award $0 +822K $0.00 822K Feb 10, 2025 Common Stock 822K Direct F1, F2
transaction IBRX Stock Option (right to buy) Award $0 +2.81M $0.00 2.81M Feb 10, 2025 Common Stock 2.81M $3.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.
F3 Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 10, 2025.

Remarks:

Founder, Executive Chairman, Global Chief Scientific and Medical Officer